Hair Restore Lite Scalp Solution (Minoxidil / Azelaic Acid) (60 mL)

Hair Restore Lite Scalp Solution is a topical treatment designed to address hair thinning and hair loss in individuals with androgenetic alopecia or other types of scalp-related conditions. It is often marketed as a milder version of traditional hair restoration treatments, containing active ingredients aimed at promoting hair growth and reducing hair shedding without the stronger side effects associated with some other formulations.
The formulation typically includes Minoxidil, along with other active ingredients designed to stimulate the scalp and encourage healthy hair growth. The “Lite” version may have a lower concentration of Minoxidil or additional ingredients for gentler application, suitable for individuals with sensitive skin or early stages of hair loss.

The active ingredients in Hair Restore Lite work by stimulating blood flow to the scalp, which provides essential nutrients to hair roots. It also helps to balance oil production and maintain scalp moisture, preventing dryness and irritation. Additionally, the solution supports the hair’s natural growth cycle by prolonging the growth phase and reducing hair shedding. Antioxidants and soothing agents in the formula protect the scalp from environmental stress and promote healthier hair development.

This solution is not recommended for people with known allergies to any of its ingredients. It should not be applied on broken skin, open wounds, or areas with severe scalp infections. Before starting treatment, it’s important to perform a patch test to check for possible sensitivity. Avoid using other hair products simultaneously unless advised by a healthcare provider. If unusual irritation, rash, or discomfort occurs, discontinue use immediately and seek medical advice.

There is limited research on the safety of Hair Restore Lite Scalp Solution during pregnancy and breastfeeding. It is advisable to consult a healthcare provider before use if you are expecting or nursing. The product is intended for external use only, and care should be taken to avoid applying it near areas where it could be absorbed into the bloodstream unless otherwise directed by a medical professional.

Store this medication in its original container at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. Rhodes T, Girman CJ, Savin RC, Kaufman KD, Guo S, Lilly FR, Siervogel RM, Chumlea WC. Prevalence of male pattern hair loss in 18-49 year old men. Dermatol Surg. 1998 Dec;24(12):1330-2.
2. Dinh, Quan Q, and Rodney Sinclair. “Female Pattern Hair Loss: Current Treatment Concepts.” Clinical Interventions in Aging 2.2 (2007): 189–199. Print.
3. Ramos, Paulo Müller, and Hélio Amante Miot. “Female Pattern Hair Loss: A Clinical and Pathophysiological Review.” Anais Brasileiros de Dermatologia 90.4 (2015): 529–543. PMC. Web. 3 Oct. 2017.
4. Lee, Won-Soo, and Hae-Jin Lee. “Characteristics of Androgenetic Alopecia in Asian.” Annals of Dermatology 24.3 (2012): 243–252. PMC. Web. 3 Oct. 2017.
5. Whiting, David. (2001). Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. Journal of the American Academy of Dermatology. 45. S81-6. 10.1067/mjd.2001.117428.
6. Jerry Shapiro, M.D. Hair Loss in Women. N Engl J Med 2007; 357:1620-1630October 18, 2007DOI: 10.1056/NEJMcp072110
7. Sasmaz S1, Arican O. Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: a pilot study. Am J Clin Dermatol. 2005;6(6):403-6.
8. Passi S , Picardo M , De Luca C , Nazzaro-Porro M. Giornale Italiano di Dermatologia e Venereologia : Organo Ufficiale, Societa Italiana di Dermatologia e Sifilografia [01 Oct 1989, 124(10):455-463].
9. M. DUŠKOVÁ, H. POSPÍŠILOVÁ. The Role of Non-Aromatizable Testosterone Metabolite in Metabolic Pathways. Institute of Endocrinology, Prague, Czech Republic. Physiol. Res. 60: 253-261, 2011.
10. Elise A.OlsenM.D.,Madeline S.WeinerR.N., B.S.N. Topical minoxidil in male pattern baldness: Effects of discontinuation of treatment. Journal of the American Academy of Dermatology Volume 17, Issue 1, July 1987, Pages 97-101.
11. DeVillez RL. The Therapeutic Use of Topical Minoxidil. Dermatol Clin 1990;8:367-74.
12. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002;47:377-85.
13. Finacea (azelaic acid) topical gel package insert. Whippany, NJ: Bayer Healthcare; 2016 Aug.
14. Azelex (azelaic acid cream) 20% [package insert]. Irvine, CA: Allergan; 2013.
15. Finacea (azelaic acid) 15% topical foam package insert. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2015 Jul.
16. Sasmaz S1, Arican O. Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: a pilot study. Am J Clin Dermatol. 2005;6(6):403-6.
17. Jang S1, Lee Y, Hwang SL, Lee MH, Park SJ, Lee IH, Kang S, Roh SS, Seo YJ, Park JK, Lee JH, Kim CD. Establishment of type II 5alpha-reductase over-expressing cell line as an inhibitor screening model. J Steroid Biochem Mol Biol. 2007 Nov-Dec;107(3-5):245-52. Epub 2007 Jun 22.
18. Herskovitz, Ingrid, and Antonella Tosti. “Female Pattern Hair Loss.” International Journal of Endocrinology and Metabolism 11.4 (2013): e9860. PMC. Web. 3 Oct. 2017.
19. Ustuner, Emin Tuncay. “Cause of Androgenic Alopecia: Crux of the Matter.” Plastic and Reconstructive Surgery Global Open 1.7 (2013): e64. PMC. Web. 3 Oct. 2017.
20. Bauer JH, Alpert MA. Rapid reduction of severe hypertension with minoxidil. J Cardiovasc Pharmacol 1980;2 Suppl:S189-99.
21. Alpert MA, Bauer JH. Rapid control of severe hypertension with minoxidil. Arch Intern Med 1982;142(12):2099-104.
22. Pogatsa-Murray G, Varga L, Varga A, et al. Changes in left ventricular mass during treatment with minoxidil and cilazapril in hypertension patients with left ventricular hypertrophy. J Hum Hypertens 1997;11(3):149-56.
23. Buhl AE. Minoxidil’s action in hair follicles. J Invest Dermatol 1991;96:73S-4S.
24. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004;150:186-194.
25. Sato T, Tadokoro T, Sonoda T, et al. Minoxidil increases 17b-hydroxysteroid dehydrogenase and 5a-reductase activity of cultured human dermal papilla cells from balding scalp. J Derm Sci 1999;19:123-5.
26. Kaler SG, Patrinos ME, Lambert GH, et al. Hypertrichosis and congenital anomalies associated with maternal use of minoxidil. Pediatrics 1987;79:434-6.
27. Minoxidil tablets package insert. Corona, CA: Watson Laboratories, Inc; 2009 Jun.
28. Azelex (azelaic acid) package insert. Irvine, CA: Allergan, Inc.; 2004 May.
29. Loniten (minoxidil tablets) package insert. Kalamazoo, MI: Pharmacia; 2002 Mar.
30. American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89.
31. Valdivieso A, Valdes G, Spiro TE, et al. Minoxidil in breast milk. Ann Intern Med. 1985;102:135. Letter.
32. Loniten (minoxidil) tablets package insert. Kalamazoo, MI: Pharmacia; 2006 Feb.